Figure 2
From: The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
Rituximab-associated survival benefits based on CD44H and CD44v6 expression status. The Kaplan-Meier method was used to estimate the OS and EFS distributions with the log-rank test performed to compare the survival curves. For cases that were either CD44H+ (A and B) or CD44H- (C and D), survival outcomes after CHOP and R-CHOP treatments were compared for OS (A and C) and EFS (B and D). CHOP versus R-CHOP comparison was also made for OS (E and G) and EFS (F and H) among the CD44V6+ (E and F) and CD44v6- (G and H) subgroups.